{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:35Z","timestamp":1787181875174,"version":"build-2736575974"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011697","name":"R\u00e9gion Bretagne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004584","name":"Conseil R\u00e9gional de Bretagne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004584","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119808","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:19:38Z","timestamp":1784963978000},"page":"119808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic potential of antisense oligonucleotides in hematological malignancies"],"prefix":"10.1016","volume":"202","author":[{"given":"Elie","family":"Cousin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfie","family":"Perrudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Oundjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Quemener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Ga\u00eblle","family":"RIO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Galibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Mazurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119808_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01775-2","article-title":"Molecularly targeted therapy and immunotherapy in leukemias","author":"Cousin","year":"2026","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3390\/biomedicines13071652","article-title":"Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia","volume":"13","author":"Zhong","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119808_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107642","article-title":"New treatments for adult T-cell leukemia\/lymphoma","volume":"149","author":"Epstein-Peterson","year":"2025","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2026.119808_bib4","first-page":"536","article-title":"Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development","volume":"27","author":"Quemener","year":"2022","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.biopha.2026.119808_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500584","article-title":"Toxicity of Antisense Oligonucleotides is Determined by the Synergistic Interplay of Chemical Modifications and Nucleotide Sequences, Not by Either Factor Alone","volume":"26","author":"Bhamra","year":"2025","journal-title":"Chembiochem Eur. J. Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119808_bib6","first-page":"321","article-title":"BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium","volume":"8","author":"Oblimersen: Augmerosen","year":"2007","journal-title":"Drugs RD"},{"key":"10.1016\/j.biopha.2026.119808_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.clml.2021.07.016","article-title":"A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies","volume":"21","author":"Harb","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.biopha.2026.119808_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2026.119808_bib9","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-10-1932","article-title":"Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study","volume":"16","author":"Talbot","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10637-013-9935-x","article-title":"Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML)","volume":"31","author":"Erba","year":"2013","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.biopha.2026.119808_bib11","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-08-0161","article-title":"SPC3042: a proapoptotic survivin inhibitor","volume":"7","author":"Hansen","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MPH.0b013e3182a8f58f","volume":"36","author":"Raetz","year":"2014","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/13543784.2013.789498","article-title":"XIAP antisense therapy with AEG 35156 in acute myeloid leukemia","volume":"22","author":"Katragadda","year":"2013","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2026.119808_bib14","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2008.19.5677","article-title":"Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer","volume":"27","author":"Dean","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2011.03.033","article-title":"Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study","volume":"11","author":"Schimmer","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.biopha.2026.119808_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2012.06.015","article-title":"Pulling the plug on a cancer cell by eliminating XIAP with AEG35156","volume":"332","author":"LaCasse","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119808_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/157488706778250050","article-title":"S. Sim\u00f5es, Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality","volume":"1","author":"Moreira","year":"2006","journal-title":"Rev. Recent. Clin. Trials"},{"key":"10.1016\/j.biopha.2026.119808_bib18","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen","volume":"27","author":"O\u2019Brien","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2005.10.025","article-title":"A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse","volume":"30","author":"Moore","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2026.119808_bib20","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","article-title":"Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2026.119808_bib21","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1200\/JCO.2005.09.118","article-title":"Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity","volume":"23","author":"Marcucci","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib22","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.18632\/oncotarget.9872","article-title":"PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin\u2019s lymphoma","volume":"7","author":"Ebrahim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119808_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.clml.2021.07.016","article-title":"A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies","volume":"21","author":"Harb","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.biopha.2026.119808_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1538-7445.AM2021-939","article-title":"Abstract 939: The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells","volume":"81","author":"Gagliardi","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib25","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.biopha.2026.119808_bib26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1200\/JCO.1996.14.4.1320","article-title":"Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies","volume":"14","author":"Bishop","year":"1996","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/scd.1.1997.6.441","article-title":"Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome","volume":"6","author":"Bishop","year":"1997","journal-title":"J. Hematother."},{"key":"10.1016\/j.biopha.2026.119808_bib28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cncr.26292","article-title":"Phase II Randomized Study of p53 Antisense Oligonucleotide (Cenersen) plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia","volume":"118","author":"Cortes","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119808_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/10428194.2011.610012","article-title":"Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia","volume":"53","author":"Lanasa","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2026.119808_bib30","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1158\/1078-0432.CCR-08-0109","article-title":"Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia","volume":"14","author":"Klisovic","year":"2008","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib31","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3109\/10428194.2016.1146947","article-title":"A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study","volume":"57","author":"Kirschbaum","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2026.119808_bib32","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-07-1320","article-title":"A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia","volume":"14","author":"Klisovic","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119808_bib34","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1172\/JCI120156","article-title":"Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells","volume":"128","author":"Shastri","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119808_bib35","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-22-2483","article-title":"Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment","volume":"29","author":"Roschewski","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: From bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.biopha.2026.119808_bib37","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.csbj.2025.09.022","article-title":"ASOG: AntiSense Oligonucleotide Generator","volume":"27","author":"Kimi","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2026.119808_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fgene.2012.00102","article-title":"siRNA Design Software for a Target Gene-Specific RNA Interference","volume":"3","author":"Naito","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.biopha.2026.119808_bib39","doi-asserted-by":"crossref","first-page":"W39","DOI":"10.1093\/nar\/gkaf392","article-title":"ASOptimizer: optimizing chemical diversity of antisense oligonucleotides through deep learning","volume":"53","author":"Kang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119808_bib40","article-title":"Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","author":"Sang","year":"2024","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-61779-424-7_25","article-title":"Silencing of gene expression by gymnotic delivery of antisense oligonucleotides","volume":"815","author":"Soifer","year":"2012","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"10.1016\/j.biopha.2026.119808_bib43","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1158\/1078-0432.CCR-08-2610","article-title":"G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis","volume":"15","author":"Stein","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib44","doi-asserted-by":"crossref","first-page":"40463","DOI":"10.1021\/acsomega.3c05144","article-title":"Peptide Conjugates of a 2\u2032-O-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes","volume":"8","author":"Hill","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119808_bib45","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated Safety Assessment of 2\u2019-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel Frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119808_bib47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119808_bib48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1089\/nat.2018.0772","article-title":"Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs","volume":"29","author":"Gagnon","year":"2019","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib49","doi-asserted-by":"crossref","unstructured":"Y. Li, G. Garcia, V. Arumugaswami, F. Guo, Structure-based design of antisense oligonucleotides that inhibit SARS-CoV-2 replication, (2021). https:\/\/doi.org\/10.1101\/2021.08.23.457434.","DOI":"10.1101\/2021.08.23.457434"},{"key":"10.1016\/j.biopha.2026.119808_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of Antisense Drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2026.119808_bib51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119808_bib52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119808_bib53","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.biopha.2026.119808_bib54","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2174\/1389200224666230418092626","article-title":"Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond","volume":"24","author":"Jiang","year":"2023","journal-title":"Curr. Drug. Metab."},{"key":"10.1016\/j.biopha.2026.119808_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.121204","article-title":"Analysis of lipid-oligonucleotide conjugates by cyclodextrin-modified capillary zone electrophoresis","volume":"219","author":"Barakat","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.biopha.2026.119808_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/108729002760070849","article-title":"Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action","volume":"12","author":"Manoharan","year":"2002","journal-title":"Antisense Nucleic Acid. Drug. Dev."},{"key":"10.1016\/j.biopha.2026.119808_bib57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cgt.2016.33","article-title":"Coinhibition of overexpressed genes in acute myeloid leukemia subtype M2 by gold nanoparticles functionalized with five antisense oligonucleotides and one anti-CD33(+)\/CD34(+) aptamer","volume":"23","author":"Zaimy","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1287128","article-title":"A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML","volume":"2016","author":"Yuan","year":"2016","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.biopha.2026.119808_bib59","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2119\/molmed.2015.00210","article-title":"Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate","volume":"22","author":"Satake","year":"2016","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2026.119808_bib60","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/mp5008212","article-title":"CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119808_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122074","article-title":"Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles","volume":"625","author":"Yan","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119808_bib62","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","article-title":"Efficient RNA drug delivery using red blood cell extracellular vesicles","volume":"9","author":"Usman","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119808_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65623-y","article-title":"Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules","volume":"14","author":"Biagiotti","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119808_bib64","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119808_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500584","article-title":"Toxicity of Antisense Oligonucleotides is Determined by the Synergistic Interplay of Chemical Modifications and Nucleotide Sequences, Not by Either Factor Alone","volume":"26","author":"Bhamra","year":"2025","journal-title":"Chembiochem Eur. J. Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119808_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119808_bib67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-08462-1","article-title":"Rapid and scalable personalized ASO screening in patient-derived organoids","volume":"638","author":"Means","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119808_bib68","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2147\/RMHP.S260641","article-title":"Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review","volume":"13","author":"Kacetl","year":"2020","journal-title":"Risk Manag. Healthc. Policy"},{"key":"10.1016\/j.biopha.2026.119808_bib69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2026.119808_bib70","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2174\/156800907783220471","article-title":"IAPs as a target for anticancer therapy","volume":"7","author":"Danson","year":"2007","journal-title":"Curr. Cancer Drug. Targets"},{"key":"10.1016\/j.biopha.2026.119808_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fonc.2014.00003","article-title":"Inhibitor of Apoptosis Proteins in Pediatric Leukemia: Molecular Pathways and Novel Approaches to Therapy","volume":"4","author":"Fulda","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3324\/haematol.10675","article-title":"Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia","volume":"92","author":"Troeger","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2026.119808_bib73","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/molecules31132283","article-title":"Survivin-Targeting Antisense Oligonucleotides in Cancer Therapy","volume":"31","author":"Poudel","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119808_bib74","doi-asserted-by":"crossref","unstructured":"Y. Li, S. Chen, K. Rahimizadeh, Z. Zhang, R.N. Veedu, Inhibition of survivin by 2\u2032-O-methyl phosphorothioate-modified steric-blocking antisense oligonucleotides, RSC Adv. 14 (n.d.) 13336\u201313341. https:\/\/doi.org\/10.1039\/d4ra01925c.","DOI":"10.1039\/D4RA01925C"},{"key":"10.1016\/j.biopha.2026.119808_bib75","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1200\/JCO.2009.21.8172","article-title":"Phase I\/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia","volume":"27","author":"Schimmer","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/ard.1994.4.71","article-title":"Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of bcl-2 Gene Expression","volume":"4","author":"Kitada","year":"1994","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.biopha.2026.119808_bib77","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.cco.0000142074.67968.eb","article-title":"Bcl-2 antisense therapy in hematologic malignancies","volume":"16","author":"Chanan-Khan","year":"2004","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib78","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(96)11103-X","article-title":"BCL-2 antisense therapy in patients with non-Hodgkin lymphoma","volume":"349","author":"Webb","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119808_bib79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/108729002760220798","article-title":"Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment","volume":"12","author":"Klasa","year":"2002","journal-title":"Antisense Nucleic Acid. Drug. Dev."},{"key":"10.1016\/j.biopha.2026.119808_bib80","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","article-title":"Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia","volume":"101","author":"Marcucci","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119808_bib81","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cmdc.201000156","article-title":"Off-target effects related to the phosphorothioate modification of nucleic acids","volume":"5","author":"Winkler","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2026.119808_bib82","series-title":"clinicaltrials.gov","article-title":"A Phase I\/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory\/Relapsed Acute Myeloid Leukemia (AML)","author":"Bio-Path Holdings, Inc","year":"2025"},{"key":"10.1016\/j.biopha.2026.119808_bib83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/pharmaceutics14010097","article-title":"Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119808_bib84","first-page":"1243","article-title":"Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts","volume":"31","author":"Tari","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02191-0","article-title":"Nucleic acid therapeutics as differentiation agents for myeloid leukemias","author":"Kovecses","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2026.119808_bib86","author":"Bio-Path Holdings, Inc","year":"2025","journal-title":"Clin. Gov."},{"key":"10.1016\/j.biopha.2026.119808_bib87","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12964-026-02932-x","article-title":"Synthetic lethality in cancer: mechanism exploration and therapeutic applications","volume":"24","author":"Zhao","year":"2026","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.biopha.2026.119808_bib88","first-page":"2802","article-title":"GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors","volume":"63","author":"Lee","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib89","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/biomedicines12051086","article-title":"Hotspot DNA Methyltransferase 3A (DNMT3A) and Isocitrate Dehydrogenase 1 and 2 (IDH1\/2) mutations in acute myeloid leukemia and their relevance as targets for immunotherapy","volume":"12","author":"Struckman","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119808_bib90","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00043426-200406000-00003","article-title":"Telomere length and telomerase activity: variations with advancing age and potential role in childhood malignancies","volume":"26","author":"Polychronopoulou","year":"2004","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib91","first-page":"201","article-title":"Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia","volume":"3","author":"Yuan","year":"2002","journal-title":"Hematol. J. Off. J. Eur. Haematol. Assoc."},{"key":"10.1016\/j.biopha.2026.119808_bib92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2026.119808_bib93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-020-01175-9","article-title":"Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance","volume":"19","author":"Bhat","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119808_bib94","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/ijms23073469","article-title":"MicroRNAs in Leukemias: A Clinically Annotated Compendium","volume":"23","author":"Turk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119808_bib95","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2026.119808_bib96","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib97","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1200\/JCO.2005.09.118","article-title":"Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity","volume":"23","author":"Marcucci","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib98","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3109\/10428194.2013.838764","article-title":"Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed\/refractory acute myeloid leukemia","volume":"55","author":"Klisovic","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2026.119808_bib99","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V87.7.2878.bloodjournal8772878","article-title":"Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis","volume":"87","author":"Yamagami","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119808_bib100","first-page":"631","article-title":"Effect of WT1 antisense oligonucleotide on proliferation and apoptosis of human leukemia cells","volume":"20","author":"Wu","year":"1999","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.biopha.2026.119808_bib101","first-page":"1379","article-title":"Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells","volume":"55","author":"Kimura","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1179\/102453312X13376952196458","article-title":"Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML)","volume":"17","author":"Ding","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.biopha.2026.119808_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00504-5","article-title":"Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center","volume":"11","author":"Chen","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2026.119808_bib104","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1073\/pnas.91.10.4504","article-title":"Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide","volume":"91","author":"Skorski","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2026.119808_bib105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1126\/science.1857987","article-title":"Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides","volume":"253","author":"Szczylik","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119808_bib106","first-page":"3773","article-title":"Antisense oligodeoxyribonucleotide against the MLL-LTG19 chimeric transcript inhibits cell growth and induces apoptosis in cells of an infantile leukemia cell line carrying the t(11;19) chromosomal translocation","volume":"58","author":"Akao","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib107","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1039\/c2ib20114c","article-title":"Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A\u2013PBX1 fusion gene expression in human Pre-B leukemia","volume":"5","author":"Uckun","year":"2013","journal-title":"Integr. Biol."},{"key":"10.1016\/j.biopha.2026.119808_bib108","first-page":"303","article-title":"Design and synthesis of anti-PML-RAR alpha antisense and its effects on the growth and apoptosis of NB4 cells","volume":"20","author":"Chen","year":"1999","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.biopha.2026.119808_bib109","first-page":"283","article-title":"Effects of PML and PML-RAR alpha antisense oligonucleotides on promyelocytic leukemia cell line NB4","volume":"22","author":"Chen","year":"2000","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.biopha.2026.119808_bib110","first-page":"307","article-title":"Effects of anti-PML-RAR alpha antisense on cell morphology and expression of PML-RAR alpha mRNA and protein of NB4 cells","volume":"20","author":"Chen","year":"1999","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.biopha.2026.119808_bib111","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3727\/000000006783981152","article-title":"vitro inhibition of promyelocytic leukemia\/retinoic acid receptor-alpha (PML\/RARalpha) expression and leukemogenic activity by DNA\/LNA chimeric antisense oligos","volume":"16","author":"Caprodossi","year":"2005","journal-title":"Oncol. Res."},{"key":"10.1016\/j.biopha.2026.119808_bib112","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0000000000000926","article-title":"ATL1102 Study Group, CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS","volume":"83","author":"Limmroth","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2026.119808_bib113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-022-01709-9","article-title":"S100A8 inhibition in leukemic lymphoblasts induces sensitivity to chemotherapy and inhibition of disease relapse","volume":"39","author":"Hejazi","year":"2022","journal-title":"Med. Oncol. North. Lond. Engl."},{"key":"10.1016\/j.biopha.2026.119808_bib114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00001813-199502000-00015","article-title":"Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes","volume":"6","author":"Bertram","year":"1995","journal-title":"Anticancer. Drugs"},{"key":"10.1016\/j.biopha.2026.119808_bib115","first-page":"393","article-title":"Multidrug resistance inhibition by antisense oligonucleotide against MDR1\/mRNA in P-glycoprotein expressing leukemic cells","volume":"12","author":"Nadali","year":"2007","journal-title":"Hematol. Amst. Neth."},{"key":"10.1016\/j.biopha.2026.119808_bib116","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF02409056","article-title":"Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdr1 mRNA","volume":"3","author":"Sola","year":"1996","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.biopha.2026.119808_bib117","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.leu.2402014","article-title":"CREB antisense oligonucleotides induce non-apoptotic cell death in proliferating leukemia cells, but not normal hematopoietic cells, by a bizarre non-antisense mechanism","volume":"15","author":"Saeki","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2026.119808_bib118","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jconrel.2015.11.015","article-title":"Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody, J. Control. Release Off","volume":"220","author":"Meissner","year":"2015","journal-title":"J. Control. Release Soc."},{"key":"10.1016\/j.biopha.2026.119808_bib119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chembiol.2023.09.005","article-title":"Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges","volume":"31","author":"Hofman","year":"2024","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119808_bib120","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.omtn.2020.11.022","article-title":"Separation-related rapid nuclear transport of DNA\/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking","volume":"23","author":"Ono","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119808_bib121","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s10637-019-00862-9","article-title":"Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells","volume":"38","author":"Hoshiko","year":"2020","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.biopha.2026.119808_bib122","doi-asserted-by":"crossref","first-page":"10760","DOI":"10.1021\/acsami.1c00016","article-title":"A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides","volume":"13","author":"Xu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biopha.2026.119808_bib123","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biomaterials.2018.12.033","article-title":"Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo","volume":"197","author":"Ma","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119808_bib124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jconrel.2006.12.021","article-title":"Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy","volume":"119","author":"Zhao","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119808_bib125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119808_bib126","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13255","article-title":"CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia","volume":"55","author":"Chen","year":"2022","journal-title":"Cell. Prolif."},{"key":"10.1016\/j.biopha.2026.119808_bib127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s11671-019-3232-3","article-title":"One-step, Rapid and Green Synthesis of Multifunctional Gold Nanoparticles for Tumor-Targeted Imaging and Therapy","volume":"15","author":"Yin","year":"2020","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.biopha.2026.119808_bib128","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/1078-0432.CCR-05-0106","article-title":"Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells","volume":"11","author":"Opalinska","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119808_bib129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular Uptake and Intracellular Trafficking of Oligonucleotides","volume":"87","author":"Juliano","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119808_bib130","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119808_bib131","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1093\/nar\/gkz214","article-title":"Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines","volume":"47","author":"Linnane","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119808_bib132","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119808_bib133","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3835(99)00441-3","article-title":"Limited synergistic effect of antisense oligonucleotides against bcr-abl and transferrin receptor mRNA in leukemic cells in culture","volume":"152","author":"Vasconcelos","year":"2000","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119808_bib134","doi-asserted-by":"crossref","unstructured":"M. Yanagidaira, K. Yoshioka, T. Nagata, S. Nakao, K. Miyata, T. YokotaEffects of cocktail combinations of antisense oligonucleotides on potency, 2022. https:\/\/doi.org\/10.21203\/rs.3.rs-2127573\/v1..","DOI":"10.21203\/rs.3.rs-2127573\/v1"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:45:43Z","timestamp":1787179543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":134,"alternative-id":["S0753332226008449"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119808","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of antisense oligonucleotides in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119808"}}